Drug intelligence / Profile preview

DNX-8000

Development stage: Preclinical
Lead developer: Dynamix Pharmaceuticals
Modality: Small Molecules

Overview

DNX-8000 is a small molecule therapeutic candidate currently under development by DynamX (also known as Dynamix Pharmaceuticals) for the treatment of cancer. As of 2024, the asset is in the optimization phase of preclinical development. While the specific biological target and mechanism of action have not been publicly disclosed by the sponsor, the program is part of DynamX's oncology pipeline focused on small molecule discovery.

Beyond the preview

Go deeper on DNX-8000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNX-8000.

Explore the full profile